|
|
CTB |
|
Vaxjo ID |
215 |
|
Vaccine Adjuvant Name |
CTB |
|
Alternative Names |
Cholera toxin subunit B |
|
Adjuvant VO ID |
VO_0005587
|
|
Description |
CTB (Cholera toxin subunit B) can be used as a genetic adjuvant to enhance systemic immune responses and as a potent adjuvant to improve both systemic and mucosal T-cell responses. |
|
Stage of Development |
Research |
|
Components |
CTB (Cholera toxin subunit B) can be used as a genetic adjuvant to enhance the systemic immune responses |
|
Preparation |
Constructed as part of DNA and recombinant Tiantan vaccinia (rTTV) vaccines expressing OVA-CTB fusion antigen. |
|
Dosage |
The paper describes immunization regimens in mice but not specific dosages for CTB itself. |
|
Function |
We constructed DNA and recombinant Tiantan vaccinia (rTTV) vaccines expressing an OVA-CTB fusion antigen. Female C57BL/6 mice were immunized with intranasal DNA priming followed by intramuscular rTTV boosting. OVA-specific T-cell responses were assessed by IFN-γ ELISPOT, and antibody responses by ELISA. Compared to the non-adjuvant group (pSV-OVA/rTTV-OVA), the pSV-OVA-CTB/rTTV-OVA-CTB regimen significantly enhanced T-cell responses in the spleen (1562 ± 567 vs. 330 ± 182 SFCs/10⁶ cells, P < 0.01), mesenteric lymph nodes (96 ± 83 vs. 1 ± 2, P < 0.05), respiratory tract draining lymph nodes (109 ± 60 vs. 2 ± 2, P < 0.01), and female genital tract (89 ± 48 vs. 23 ± 21, P < 0.01). These findings demonstrate that CTB fusion acts as a potent adjuvant to boost systemic and mucosal T-cell responses. |
| References |
Qiu et al., 2014: Qiu S, Ren X, Ben Y, Ren Y, Wang J, Zhang X, Wan Y, Xu J. Fusion-expressed CTB improves both systemic and mucosal T-cell responses elicited by an intranasal DNA priming/intramuscular recombinant vaccinia boosting regimen. Journal of immunology research. 2014; 2014; 308732. [PubMed: 24741585].
|
|
